ArticleTheranostics2018
Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 103 citations in OpenAlex.
- Endothelium-targeted and untargeted nanoparticle therapies in thromboinflammatory vascular diseases.Blood vessels, thrombosis & hemostasis · 2026Review
- From bench to bedside: Overcoming translational hurdles in nanoparticle research with pharmacokinetic modeling.Bioengineering & translational medicine · 2026Review
- Biological Safety Analysis of Nanoparticles: Exploring Toxicity, Mechanisms, and Safety Factors for Pharmaceuticals.International journal of nanomedicine · 2026Review
- Advances in the application of lipid nanocapsules and nanostructured carriers in the treatment of lung cancer.Nanomedicine (London, England) · 2025Review
- Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization.Pharmaceutics · 2025Review
- Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review".BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- The benefits and risks of PEGylation in nanomedicine.Nature nanotechnology · 2025Article
- Better the devil you know than the devil you don't - PEG challenges in nanomedicine.Nature nanotechnology · 2025Article
- Synergistic effects of thermosensitive liposomal doxorubicin, mild hyperthermia, and radiotherapy in breast cancer management: an orthotopic mouse model study.Drug delivery and translational research · 2025Article
- Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Article
- Impact of the Hydrophilicity of Poly(sarcosine) on Poly(ethylene glycol) (PEG) for the Suppression of Anti-PEG Antibody Binding.ACS omega · 2024Article
- Vaccines and the Eye: Current Understanding of the Molecular and Immunological Effects of Vaccination on the Eye.International journal of molecular sciences · 2024Review
- Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol.Organic process research & development · 2024Review
- Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design.Acta pharmaceutica Sinica. B · 2024Review
- Impact of Pre-existing Anti-polyethylene Glycol Antibodies on the Pharmacokinetics and Efficacy of a COVID-19 mRNA Vaccine (Comirnaty) In Vivo.Biomaterials research · 2024Article
- Development of Poly(sorbitol adipate)-Gels (Basel, Switzerland) · 2023Article
- Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Tissue engineering modalities in skeletal muscles: focus on angiogenesis and immunomodulation properties.Stem cell research & therapy · 2023Review
- Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines.ACS nano · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Yuan-Chin HsiehGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan First Road, Kaohsiung 80708, Taiwan.
Hsin-Ell WangDepartment of Biomedical Imaging and Radiological Sciences and Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.
Wen-Wei LinGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan First Road, Kaohsiung 80708, Taiwan.
Steve R RofflerInstitute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Taipei 11529, Taiwan.
Ta-Chun ChengCenter for Biomarkers and Biotech Drugs, Kaohsiung Medical University, 100 Shih-Chuan First Road, Kaohsiung 80708, Taiwan.
Yu-Cheng SuInstitute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Taipei 11529, Taiwan.
Jia-Je LiDepartment of Biomedical Imaging and Radiological Sciences and Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.
Chao-Cheng ChenDepartment of Biomedical Imaging and Radiological Sciences and Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.
Chun-Han HuangDepartment of Biomedical Imaging and Radiological Sciences and Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.
Bing-Mae ChenInstitute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Taipei 11529, Taiwan.
Jaw-Yuan WangCenter for Biomarkers and Biotech Drugs, Kaohsiung Medical University, 100 Shih-Chuan First Road, Kaohsiung 80708, Taiwan.
Tian-Lu ChengGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan First Road, Kaohsiung 80708, Taiwan.
Fang-Ming ChenCenter for Biomarkers and Biotech Drugs, Kaohsiung Medical University, 100 Shih-Chuan First Road, Kaohsiung 80708, Taiwan.
Kaohsiung Medical University · TWNational Yang Ming Chiao Tung University · TWInstitute of Biomedical Sciences, Academia Sinica · TWKaohsiung Municipal Ta-Tung Hospital · TWNational Sun Yat-sen University · TW
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntibiotics, AntineoplasticAntibodiesDoxorubicinFemaleLiposomesMiceMice, Inbred BALB CNeoplasms, ExperimentalNeoplasm TransplantationPolyethylene GlycolsAntibiotics, AntineoplasticAntibodiesDoxorubicinliposomal doxorubicinLiposomesPolyethylene Glycolsanti-PEG antibodiesELISALipoDoxliposomePEGPolyethylene glycol
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.